Clinical Trials Logo

Stage IB Breast Cancer clinical trials

View clinical trials related to Stage IB Breast Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01800422 Active, not recruiting - Clinical trials for Stage II Breast Cancer

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether or not the medication that blocks the effects of the hormone progesterone (CDB-4124 or Proellex) will decrease the growth rate of breast cancer cells as compared to a placebo. CDB-4124 (also called Proellex) is a medication that works against the hormone, progesterone. The researchers in this study would like to compare changes in breast cancer cells of women who have taken CDB-4124 prior to surgery to those from women who have taken a placebo pill prior to surgery.

NCT ID: NCT01372579 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving eribulin mesylate and carboplatin together before surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT00066690 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

SOFT
Start date: December 17, 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.